The HIF‐PHI BAY 85‐3934 (Molidustat) Improves Anemia and Is Associated With Reduced Levels of Circulating FGF23 in a CKD Mouse Model
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Bone and Mineral Research"
DOI: 10.1002/jbmr.4272
Abstract: Fibroblast growth factor‐23 (FGF23) is a critical factor in chronic kidney disease (CKD), with elevated levels causing alterations in mineral metabolism and increased odds for mortality. Patients with CKD develop anemia as the kidneys progressively… read more here.
Keywords: bay; hif phi; ckd mice; ckd ... See more keywords
Explore the effect of HIF-PHI on blood pressure variation rate and anemia efficacy in maintenance hemodialysis patients
Sign Up to like & getrecommendations! Published in 2025 at "BMC Nephrology"
DOI: 10.1186/s12882-024-03928-w
Abstract: This study aims to investigate the impact of hypoxia-inducing factor prolyl hydroxylase inhibitor (HIF-PHI), specifically Roxadustat, on blood pressure variability, blood pressure indices, hemoglobin, and other biochemical markers in maintenance hemodialysis (MHD) patients. In this… read more here.
Keywords: pressure; roxadustat; hif phi; blood ... See more keywords
Bibliometric analysis of hypoxia inducible factor prolyl hydroxylase inhibitor in anemia
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.1005225
Abstract: Objective: This study aimed to explore the global research status, hot topics, and future prospects in the field of the hypoxia inducible factor prolyl hydroxylase inhibitor (HIF-PHI) by bibliometric analysis. Methods: The literatures about HIF-PHI… read more here.
Keywords: pharmacology; hypoxia inducible; hif phi; phi ... See more keywords